SCHEMBL5536023

SCHEMBL5536023

CCCCC(=O)OCc1nnn[nH]1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.40
CYP3A4 P08684 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
HPGD P15428 1/20 0.40
CYP2C19 P33261 1/20 0.40
DGKA P23743 1/20 0.40
PAM P19021 2/20 0.37
LMNA P02545 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
P2RX7 Q99572 1/20 0.36
TSHR P16473 2/20 0.35
MAPT P10636 1/20 0.35
ELANE P08246 2/20 0.35
DNM1 Q05193 1/20 0.34
ALDH1A1 P00352 1/20 0.34
ATM Q13315 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5543408 0.95 DGKA (0.46) DGKAPAMLMNAP2RX7TSHR
SCHEMBL5546880 0.94 DGKA (0.49) DGKAPAMLMNAP2RX7TSHR
SCHEMBL5537649 0.90 ALDH1A1 (0.36) L3MBTL1CYP3A4CYP1A2CYP2D6CYP2C9
SCHEMBL5540795 0.83 ALDH1A1 (0.33) CYP1A2HPGDCYP2C19ALDH1A1
SCHEMBL9641762 0.78 CYP1A2 (0.43) CYP3A4CYP1A2CYP2D6CYP2C9HPGD
SCHEMBL17242958 0.77 CYP4F2 (0.44) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL17665568 0.75 LMNA (0.42) L3MBTL1HPGDDGKALMNATDP1
SCHEMBL443306 0.70 CA12 (0.56) HPGDLMNAALDH1A1ATM
SCHEMBL10435626 0.70 DGKA (0.41) DGKAPAMLMNATSHRMAPT
SCHEMBL9277688 0.69 DGKA (0.43) DGKAPAMLMNATSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 L3MBTL1 1931/4885CYP3A4 1683/4885CYP1A2 659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.